Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

Thu, 28th Nov 2019 11:56

(Alliance News) - Faron Pharmaceuticals Ltd said Thursday US regulators approved its Clevegen cancer treatment as an investigational new drug, allowing the expansion of a clinical trial into the US.

Shares in Faron were 37% higher at 225.80 pence in London on Thursday following the announcement.

The US Food & Drug Administration approved the IND application for Clevegen, an immunotherapy targeting tumour associated with macrophages in some metastatic or inoperable solid tumours.

The drug is currently undergoing the Matins clinical trial in Europe. Following FDA approval, Faron anticipates to open new study sites in the US.

"We are very pleased to receive this IND approval from the FDA, marking another milestone in the development of Clevegen," Chief Executive Officer Markku Jalkanen said.

"This approval will allow us to expand Matins into the US using the same protocol both in Europe and in the US, accelerating our understanding of this novel precision medicine in cancer patients who are refractory to all other treatment options and streamlining the regulatory processes," Jalkanen added. "With the US IND now approved, in due course, we plan to file applications for Breakthrough status in the US and Prime status in Europe, further facilitating regulatory interactions during the development of Clevegen."

By Ahren Lester; ahrenlester@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Related Shares

More News
18 Mar 2024 17:09

LONDON MARKET CLOSE: Stocks downbeat before central bank rate storm

(Alliance News) - Stocks in London closed in the red on Monday, as tech gains in New York failed to make an impact ahead of several interest rate deci...

18 Mar 2024 14:14

Faron shares jump on encouraging trial data

(Sharecast News) - Faron Pharmaceuticals announced further encouraging data from the first phase of its 'BEXMAB' trial on Monday, targeting higher-ris...

18 Mar 2024 11:41

Faron Pharmaceuticals shares jump on positive data from Bexmab study

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said a study showed more patients responding to treatment in a new readout of the Bexmab study f...

18 Mar 2024 10:05

AIM WINNERS & LOSERS: Clontarf raises GBP400,000; Faron jumps

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

13 Mar 2024 20:49

EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.